

VIRTUAL CONNECTIONS. REAL VALUE.



LYTHAM  
PARTNERS

# FALL 2022

## INVESTOR CONFERENCE



VIRTUAL CONNECTIONS. REAL VALUE.

### WHO WE ARE.

Lytham Partners is one of the country's leading investor relations firms. With more than two decades of Corporate Access experience, we have built one of the industry's most diverse and effective platforms for connecting small cap companies with high quality and focused institutional investors.

### OUR MISSION.

The mission of the Lytham Partners Investor Conference Series is to create value for small cap companies through virtual connections with high-quality institutional investors. Our conference series has featured more than 170 companies from various industries including healthcare & pharma, consumer, technology, industrials & special situations, clean tech, and financial services. Some highlights of our event include virtual 1x1 meetings, webcast presentations, engaging fireside chats and panels on special topics within the industry.



#### MEETINGS THAT MATTER

We focus on connecting companies with high-quality investors to provide the biggest and best impact. In 2021 alone our conferences connected **150+** companies with **1,000+** investors for over **3,000** 1x1 meetings.



#### VALUE THAT LASTS

You will continue to reap benefits far past the end of the event. By participating in our conference, your company can get valuable content to help increase awareness and expand your reach among investors and stakeholders.

#### CONTACT US!

For more information on our Fall 2022 Investor Conference, please call 602.889.9700 or email us at [conference@lythampartners.com](mailto:conference@lythampartners.com)

## INDUSTRY PANELS

### ORPHAN DRUGS: INNOVATIVE COMPANIES ADDRESSING RARE DISEASES

Wednesday, September 28th @ 2PM ET

Join us as we talk with executives from three innovative companies that are addressing rare orphan designated diseases. We will discuss the differences in regulatory pathways, government incentives and exclusivities, financial opportunities, and what it means to bring cures to patients that frequently have no other options.



**MODERATOR**  
Robert Blum  
Managing Partner,  
Lytham Partners



Josh Disbrow  
Chairman & CEO,  
Aytu BioPharma, Inc.  
(NASDAQ: AYTU)



Jan D'alvise  
President & CEO,  
Acasti Pharma  
(NASDAQ: ACST / TSXV: ACST)



Lisa Conte  
Founder & CEO,  
Jaguar Health, Inc.  
(NASDAQ: JAGX)

### ENERGY INVESTING: THE NEXT SUPERCYCLE, IS IT CARBON BASED OR GREEN OR BOTH?

Thursday, September 29th @ 2PM ET

Join us as we discuss the future of energy investing. Energy prices have gone up across the board leading many to believe we have entered a new supercycle for energy.



**MODERATOR**  
Adam Lowenstein  
Vice President,  
Lytham Partners



Kyle Loudermilk  
President & CEO,  
GSE Systems, Inc.  
(NASDAQ: GVP)



Jim Rakievich  
President & CEO,  
McCoy Global, Inc.  
(TSX: MCB)

### COMPANY LIST

**P** = Presenting Company

Updated as of September 26, 2022.  
Participation subject to change

## BASIC MATERIALS

- Arianne Phosphate (TSXV: DAN / PINK: DRRSF)
- P** Vox Royalty Corp. (OTCQX: VOXCF)

## CLEANTECH

- LiqTech International, Inc. (NASDAQ: LIQT)

## ENERGY

- Civeo Corporation (NYSE: CVEO)
- P** Crew Energy Inc. (OTCQB: CWEGF)
- P** GSE Systems Inc. (NASDAQ: GVP)

## FINTech

- AppTech Payments Corp. (NASDAQ: APCX)
- BIGG Digital Assets (CSE: BIGG / OTCQX: BBKCF)
- Mogo Inc. (NASDAQ: MOGO / TSX: MOGO)
- Payfare Inc. (TSX: PAY / PINK: PYFRF)
- TAAL Distributed Information Technologies (CSE: TAAL / OTCQX: TAALF)

## INDUSTRIALS

- AZZ Inc. (NYSE: AZZ)
- P** Commercial Vehicle Group, Inc. (NASDAQ: CVGI)
- S&W Seed Company (NASDAQ: SANW)
- P** SenesTech Inc. (NASDAQ: SNES)

## HEALTHCARE

- P** Acasti Pharma (NASDAQ: ACST / TSXV: ACST)
- P** Augmedix, Inc. (NASDAQ: AUGX)
- P** Aurora Spine Corp. (TSXV: ASG / OTCQB: ASAPF)
- P** Aytu BioPharma, Inc. (NASDAQ: AYTU)
- Cosmos Holdings, Inc. (NASDAQ: COSM)
- Delcath Systems (NASDAQ: DCTH)
- P** Immucell Corp. (NASDAQ: ICCG)
- INVO Bioscience (NASDAQ: INVO)
- P** Jaguar Health, Inc. (NASDAQ: JAGX)
- LifeMD, Inc. (NASDAQ: LFMD)
- P** Mannkind Corporation (NASDAQ: MNKD)
- MediciNova, Inc. (NASDAQ: MNOV)
- OpSens Inc. (TSX: OPS / OTCQX: OPSSF)
- Perimeter Medical Imaging (TSXV: PINK / PINK: PYNKF)
- P** Reliq Health Technologies Inc. (TSXV: RHT / PINK: RQHTF)
- P** Reviva Pharmaceuticals Holdings (NASDAQ: RVPH)
- P** Scientific Industries, Inc. (OTCQB: SCND)
- VolitionRx Limited (NYSE American: VNRX)

## TECHNOLOGY

- CHAR Technologies Ltd. (TSXV: YES)
- P** LiveWorld, Inc. (PINK: LVWD)
- P** Nano Dimension Ltd. (NASDAQ: NNDM)
- Peraso Inc. (NASDAQ: PRSO)
- P** Precision Optics Corporation (OTCQB: PEYE)
- Xybion Digital Inc. (TSXV: XYBN)
- Zoomd Technologies (TSXV: ZOMD / OTC: ZMDTF)

### CONTACT US!

For more information on our Fall 2022 Investor Conference, please call 602.889.9700 or email us at [conference@lythampartners.com](mailto:conference@lythampartners.com)



## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### ACASTI PHARMA (NASDAQ: ACST / TSXV: ACST)

**Healthcare | Market Cap: \$40M**

Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Acasti's novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery—all which could help to increase treatment compliance and improve patient outcomes. Acasti's three lead clinical assets have each been granted Orphan Drug Designation by the U.S. FDA, which provide the assets with seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection with over 40 granted and pending patents. Acasti's lead clinical assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosal spray targeting Ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily affects children, causing severe disability, and for which no treatment currently exists; and (iii) GTX-101, a topical spray targeting Postherpetic Neuralgia (PHN), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years.

### APPTech PAYMENTS CORP. (NASDAQ: APCX)

**FinTech | Market Cap: \$11M**

AppTech Payments Corp., is a financial technology company, provides electronic payment processing technologies and merchant services in the United States. Its merchant services offer financial processing for businesses to accept cashless payments, such as credit cards, automatic clearing house, and wireless payments. The company's merchant services software offers integrated solutions, such as data encryption, payment tokenization, issuing banking authorization, and the creation of white-label and merchant-specific mobile applications for friction less digital and mobile payment acceptance, including acceptance of alternative payment methods, as well as multi-use case, multi-channel, API-driven, and account-based issuer processing for card, digital tokens, and payment transfer transactions. It is developing mobile payment platform relies on SMS text messaging.

### ARIANNE PHOSPHATE (TSXV: DAN / PINK: DRRSF)

**Basic Materials | Market Cap: \$72M**

Arianne Phosphate ("Arianne Phosphate Inc.") ([www.arianne-inc.com](http://www.arianne-inc.com)) is developing the Lac à Paul phosphate deposits located approximately 200 km north of the Saguenay/Lac St. Jean area of Quebec, Canada. These deposits will produce a high-quality igneous apatite concentrate grading 39% P2O5 with little or no contaminants (Feasibility Study released in 2013). The Company has 185,464,469 shares outstanding.

### AUGMEDIX, INC. (NASDAQ: AUGX)

**Healthcare | Market Cap: \$60M**

Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide. The Company's Ambient Automation Platform converts the natural conversation between physicians and patients into timely and comprehensive medical notes and performs a suite of related data services. These services relieve physicians of administrative burdens to enable more time for patient care. The Augmedix proprietary platform uses automatic speech recognition, natural language processing and clinical datasets to capture the ambient visit conversation and generate a structured medical note. The structured medical note data is then used to deliver additional data services. Quality is assured by trained medical documentation specialists.

### AURORA SPINE CORP. (TSXV: ASG / OTCQB: ASAPF)

**Healthcare | Market Cap: \$33M**

Aurora Spine Corporation (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes. Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at [www.aurora-spine.com](http://www.aurora-spine.com) or [www.aurorapaincare.com](http://www.aurorapaincare.com).

### AYTU BIOPHARMA, INC. (NASDAQ: AYTU)

**Healthcare | Market Cap: \$16M**

Aytu BioPharma is a pharmaceutical company with a portfolio of commercial prescription therapeutics and consumer health products, and a growing therapeutics pipeline focused on treating rare, pediatric-onset disorders. The company's prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), as well as Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines in various formulations for infants and children with fluoride deficiency. Aytu is also building a therapeutic pipeline, which includes ARI01 (enzastaurin), a PKC inhibitor in development for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disease typically diagnosed in childhood resulting in high morbidity and a significantly shortened lifespan, and for which there are no currently approved treatments. ARI01 has received Orphan Drug designation and Fast Track designation from the U.S. Food and Drug Administration and has received Orphan Drug designation from the European Commission. Aytu is also researching and advancing the development of the Healtight ultraviolet light A (UVA) endotracheal catheter, a patented, investigational medical device with potential application in the treatment of severe, difficult-to-treat respiratory infections.

## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### **AZZ INC. (NYSE: AZZ)**

**Industrials | Market Cap: \$1B**

AZZ Inc. is a global provider of galvanizing and a variety of metal coating solutions, welding solutions, specialty electrical equipment and highly engineered services to a broad range of markets, including, but not limited to, the power generation, transmission, distribution, refining and industrial markets. AZZ's Metal Coatings segment is a leading provider of metal finishing solutions for corrosion protection, including hot-dip galvanizing, spin galvanizing, powder coating, anodizing and plating, to the North American steel fabrication industry. AZZ's Infrastructure Solutions segment is dedicated to delivering safe and reliable transmission of power from generation sources to end customers, and automated weld overlay solutions for corrosion and erosion mitigation to critical infrastructure in the energy and waste management markets worldwide.

### **BIGG DIGITAL ASSETS (CSE: BIGG / OTCQX: BBKCF)**

**FinTech | Market Cap: \$75M**

BIGG Digital Assets Inc. (BIGG) believes the future of crypto is a safe, compliant, and regulated environment. BIGG invests in products and companies to support this vision. BIGG has three portfolio companies: Netcoins (netcoins.ca), Blockchain Intelligence Group (blockchaingroup.io) and TerraZero (terrazero.com).

### **CHAR TECHNOLOGIES LTD. (TSXV: YES)**

**Technology | Market Cap: \$29M**

CHAR Technologies Ltd is a leading cleantech development and environmental services company listed on the TSXV ("YES.V"). We specialize in delivering innovative service and technology solutions that are environmentally sustainable and cost-effective for our clients.

### **CIVEO CORPORATION (NYSE: CVEO)**

**Energy | Market Cap: \$460M**

Civeo Corporation is a leading provider of hospitality services with prominent market positions in the Canadian oil sands and the Australian natural resource regions. Civeo offers comprehensive solutions for lodging hundreds or thousands of workers with its long-term and temporary accommodations and provides food services, housekeeping, facility management, laundry, water and wastewater treatment, power generation, communications systems, security and logistics services. Civeo currently operates a total of 27 lodges and villages in Canada, Australia and the U.S., with an aggregate of over 28,000 rooms. Civeo is publicly traded under the symbol CVEO on the New York Stock Exchange. For more information, please visit Civeo's website at [www.civeo.com](http://www.civeo.com).

### **COMMERCIAL VEHICLE GROUP, INC. (NASDAQ: CVGI)**

**Industrials | Market Cap: \$197M**

CVG is a leading supplier of warehouse automation and robotic assemblies, electric vehicle assemblies, electrical wire harnesses, seating systems, mechanical assemblies, structures, plastic products and more to the ecommerce, transportation, warehousing, construction equipment, industrial and recreational vehicle markets. While we are known for our strength in commercial trucks and continue to support multiple global manufacturers, we are continuing to adapt our portable capabilities and expertise into new industries, including electric vehicles, ecommerce and more.

### **COSMOS HOLDINGS, INC. (NASDAQ: COSM)**

**Healthcare | Market Cap: \$8M**

Cosmos Health is an international healthcare engaged in the nutraceuticals sector through its own proprietary lines of products "Sky Premium Life" and "Mediterranean". Cosmos Holdings Inc. is operating in the pharmaceutical sector as well, through the provision of a broad line of branded generics and OTC medications. In addition, the group is involved in the healthcare distribution sector through its subsidiaries in Greece and UK serving retail pharmacies and wholesale distributors. Cosmos Holdings Inc. is strategically focusing on the R&D of novel patented nutraceuticals (IP) and specialized root extracts as well as on the R&D of proprietary complex generics and innovative OTC products.

### **CREW ENERGY INC. (TSX: CR / OTCQB: CWEGF)**

**Energy | Market Cap: \$800M**

Crew is a growth-oriented natural gas and liquids producer, committed to pursuing sustainable per share growth through a balanced mix of financially and socially responsible exploration and development. The Company's operations are exclusively focused in the vast Montney resource, situated in northeast British Columbia, and include a large contiguous land base. Greater Septimus along with Groundbirch and the light oil area at Tower in British Columbia offer significant development potential over the long-term. The Company has access to diversified markets with operated infrastructure and access to multiple pipeline egress options.

### **DELCATH SYSTEMS (NASDAQ: DCTH)**

**Healthcare | Market Cap: \$35M**

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA). In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.



## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### GSE SYSTEMS, INC. (NASDAQ: GVP)

**Energy | Market Cap: \$24M**

As a collective group, GSE Solutions leverages top skills, expertise, and technology to provide highly specialized solutions that allow customers to achieve the performance they imagine. Our experts deliver and support end-to-end training, engineering, compliance, simulation, and workforce solutions that help the power industry reduce risk and optimize plant operations. GSE is proven, with over four decades of experience, more than 1,100 installations, and hundreds of customers in over 50 countries spanning the globe. [www.gses.com](http://www.gses.com).

### IMMUCELL (NASDAQ: ICCC)

**Healthcare | Market Cap: \$66M**

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves, and is in the late stages of developing Re-Tain®, a novel treatment for subclinical mastitis in dairy cows without a milk discard requirement that provides an alternative to traditional antibiotics.

### INVO BIOSCIENCE (NASDAQ: INVO)

**Healthcare | Market Cap: \$13M**

INVO Bioscience is a medical device company focused on creating simplified, affordable treatments for patients diagnosed with infertility. Our solution, the INVO® Procedure, is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Their lead product, the INVOcell®, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (ART). The INVOcell® is the first Intravaginal Culture (IVC) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (IVF) and Intrauterine Insemination (IUI). INVO's mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase the availability of care.

### JAGUAR HEALTH, INC. (NASDAQ: JAGX)

**Healthcare | Market Cap: \$25M**

Jaguar Health, Inc. is a San Francisco, CA-based commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Our wholly owned subsidiary, Napo Pharmaceuticals (Napo), focuses on developing and commercializing proprietary plant-based human pharmaceuticals for the global marketplace from plants or plant products used traditionally in rainforest areas. Napo's marketed drug Mytesi® (crofelemer 125 mg delayed-release tablets) is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. To date, this is the only oral plant-based botanical prescription medicine approved under the FDA's Botanical Guidance. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. Napo Therapeutics is initially focused on two key orphan target indications for crofelemer: Short bowel syndrome (SBS) with intestinal failure, and congenital diarrheal disorders (CDD). Jaguar Animal Health's Canalevia®-CA1 (crofelemer delayed-release tablets) drug is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is now available from multiple leading veterinary distributors in the U.S. to veterinarians. Crofelemer is a novel, first in class anti secretory agent which has a normalizing effect on electrolyte and fluid balance while acting locally in the gut, and this mechanism of action has the potential to benefit multiple disorders that cause gastrointestinal distress, including diarrhea and abdominal discomfort. Crofelemer is in development for additional possible human follow-on indications, including the management of diarrhea and abdominal discomfort in inflammatory bowel disease (IBD); diarrhea-predominant irritable bowel syndrome (IBS-D); and for idiopathic/functional diarrhea. A second-generation proprietary anti-secretory agent, NP-300 (lechlemer), is undergoing preclinical development for symptomatic relief and treatment of diarrhea in patients with acute infection from cholera. For more information about Jaguar Health, please visit <https://jaguar.health>. For more information about Napo Pharmaceuticals, visit [www.napopharma.com](http://www.napopharma.com).

### LIFEMD, INC. (NASDAQ: LFMD)

**Healthcare | Market Cap: \$78M**

LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men's and women's health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, affiliated 50-state medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to amazing healthcare that is affordable to everyone. To learn more, go to [ir.LifeMD.com](http://ir.LifeMD.com).

### LIQTECH INTERNATIONAL, INC. (NASDAQ: LIQT)

**CleanTech | Market Cap: \$21M**

LiqTech International, Inc., a Nevada corporation, is a clean technology company that provides state-of-the-art ceramic silicon carbide filtration technologies for gas and liquid purification. LiqTech's silicon carbide membranes are designed to be used in the most challenging purification applications, and its silicon carbide filters are used to control diesel exhaust soot emissions. Using nanotechnology, LiqTech develops products using its proprietary silicon carbide technology, resulting in a wide range of component membranes, membrane systems, and filters for both microfiltration and ultrafiltration applications. By incorporating LiqTech's SiC liquid membrane technology with the Company's extensive systems design experience and capabilities, LiqTech offers unique, turnkey solutions for the most difficult water purification applications.

## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### LIVEWORLD, INC. (OTC PINK: LVWD)

**Technology | Market Cap: \$1M**

LiveWorld is a digital agency specializing in social media and technology solutions that help companies spark emotional conversations, build stronger customer relationships, and drive behavior change. We live at the intersection of bold creative rooted in strategy that inspires, moderation that activates human interactions, and technology that enriches and scales customer experiences. With over 25 years of making connections, our integrated team leverages our social media DNA to deliver emotion driven behavior change through digital campaigns with a human touch. LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in San Jose, California, with an additional office in New York City.

### MANNKIND CORPORATION (NASDAQ: MNKD)

**Healthcare | Market Cap: \$1B**

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.

### MEDICINOVA, INC. (NASDAQ: MNOV)

**Healthcare | Market Cap: \$117M**

MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova's lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) was studied in a Phase 2 trial in patients at risk of developing acute respiratory distress syndrome (ARDS) and is also being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.

### MOGO INC. (TSX: MOGO / NASDAQ: MOGO)

**FinTech | Market Cap: \$75M**

Mogo Inc., one of Canada's leading financial technology companies, is empowering its 1.9 million members with simple digital solutions to help them get in control of their financial health while also making a positive impact with their money. Through the free Mogo app, consumers can access a digital spending account with Mogo Visa® Platinum Prepaid Card featuring automatic carbon offsetting, easily buy and sell bitcoin, get free monthly credit score monitoring and ID fraud protection and access personal loans and mortgages. Mogo's new MogoTrade app offers commission-free stock trading that helps users make a positive impact with every investment and together with Moka, Mogo's wholly-owned subsidiary bringing automated, fully-managed flat-fee investing to Canadians, forms the heart of Mogo's digital wealth platform. Mogo's wholly-owned subsidiary, Carta Worldwide, also offers a digital payments platform that powers the next-generation card programs from innovative fintech companies in Europe, North America and APAC.

### NANO DIMENSION LTD. (NASDAQ: NNDM)

**Technology | Market Cap: \$680M**

Nano Dimension's (Nasdaq: NNDM) vision is to transform the electronics and similar additive manufacturing sectors through the development and delivery of an environmentally friendly and economically efficient additive manufacturing, Industry 4.0 solution, while enabling a one-production-step-conversion of digital designs into functioning devices – on-demand, anytime, anywhere.

### OPSENS INC. (TSX: OPS / OTCQX: OPSSF)

**Healthcare | Market Cap: \$225M**

OpSens Inc. (TSX: OPS) (OTCQX: OPSSF) a cardiology medical device company providing innovative product solutions based on its patented optical technology, focuses mainly on coronary artery stenosis measurement in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.

### PAYFARE INC. (TSX: PAY / PINK: PYFRF)

**FinTech | Market Cap: \$232M**

Payfare is a global financial technology company powering digital banking and instant payment solutions for today's gig workforce. Payfare partners with leading platforms and marketplaces, such as Uber, Lyft and DoorDash, to provide financial health for their workforce.



## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### PERASO INC. (NASDAQ: PRSO)

Technology | Market Cap: \$50M

Peraso Inc. (NASDAQ: PRSO) is a pioneer in high performance 5G mmWave wireless technology, offering chipsets, modules, software and IP. Peraso supports a variety of applications, including fixed wireless access, immersive video and factory automation. In addition, Peraso's solutions for data and telecom networks focus on Accelerating Data Intelligence and Multi-Access Edge Computing, providing end-to-end solutions from the edge to the centralized core and into the cloud. For additional information, please visit [www.perasoinc.com](http://www.perasoinc.com). Peraso and the Peraso logo are registered trademarks of Peraso Inc. in the U.S. and/or other countries.

### PERIMETER MEDICAL IMAGING (TSXV: PINK / PINK: PYNKF)

Healthcare | Market Cap: \$109M

With headquarters in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company that is driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month, underscoring the company's dedication to helping surgeons, radiologists, and pathologists use Perimeter's imaging technology and AI in the fight against breast cancer, which is estimated to account for 30% of all female cancer diagnoses this year.

### PRECISION OPTICS CORPORATION (OTCQB: PEYE)

Healthcare | Market Cap: \$34M

Founded in 1982, Precision Optics is a vertically integrated optics company primarily focused on leveraging its proprietary micro-optics and 3D imaging technologies to the healthcare and defense/aerospace industries by providing services ranging from new product concept through mass manufacture. Utilizing its leading-edge in-house design, prototype, regulatory and fabrication capabilities as well as its Ross Optical division's high volume world-wide sourcing, inspecting and production resources, the Company is able to design and manufacture next-generation product solutions to the most challenging customer requirements. Within healthcare, Precision Optics enables next generation medical device companies around the world to meet the increasing demands of the surgical community who require more enhanced and smaller imaging systems for minimally invasive surgery as well as 3D endoscopy systems to support the rapid proliferation of surgical robotic systems. In addition to these next generation applications, Precision Optics has supplied top tier medical device companies a wide variety of optical products for decades, including complex endocouplers and specialized endoscopes. The Company is also leveraging its technical proficiency in micro-optics to enable leading edge defense/aerospace applications which require the highest quality standards and the optimization of size, weight and power.

### RELIQ HEALTH TECHNOLOGIES INC. (TSXV: RHT / PINK: RQHTF)

Healthcare | Market Cap: \$112M

Reliq Health Technologies is a rapidly growing global healthcare technology that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market. Reliq's powerful iUGO Care platform supports care coordination and community-based virtual healthcare. iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery. iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the WKN as A2AJTB.

### REVIVA PHARMACEUTICALS HOLDINGS (NASDAQ: RVPH)

Healthcare | Market Cap: \$44M

Reviva Pharmaceuticals Holdings is a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity.

### S&W SEED COMPANY (NASDAQ: SANW)

Industrials | Market Cap: \$40M

Founded in 1980, S&W Seed Company is a global integrated seed technology company focused on middle market crops. Headquartered in the United States and with operations in Australia, S&W's vision is to be the world's preferred proprietary seed Company which supplies a range of forage and specialty crop products that supports the growing global demand for animal proteins and healthier consumer diets. S&W is a global leader in proprietary alfalfa, sorghum and pasture seeds, with significant research and development, production and distribution capabilities. S&W's product portfolio also includes hybrid sunflower and wheat and the company is utilizing its research and breeding expertise to develop and produce stevia, the all-natural, zero calorie sweetener for the food and beverage industry.

### SCIENTIFIC INDUSTRIES, INC. (OTCQB:SCND)

Healthcare | Market Cap: \$42M

Scientific Industries (OTCQB:SCND), is a life science tool provider. It designs, manufactures, and markets laboratory equipment, including the world-renowned Vortex-Genie® 2 Mixer and Torbal® balances, and bioprocessing systems under the product name Cell Growth Quantifier and Liquid Injection System. Scientific Industries' products are generally used and designed for research purposes in laboratories of universities, hospitals, pharmaceutical companies, medical device manufacturers, and pharmacies. To learn more, visit [www.scientificindustries.com](http://www.scientificindustries.com). **Scientific Bioprocessing, Inc. ("SBI")** is dedicated to providing state-of-the-art instruments, strategies, and technologies to expedite the production of viable cells and therapies with a streamlined process and product consistency. SBI's mission is to develop sensor technologies and instruments that make cell culture and bioprocessing work easier, experiments more reproducible, and culture conditions better suited to meet experimental objectives. SBI is a subsidiary of Scientific Industries Holdings, Inc. To learn more, visit [www.scientificbio.com](http://www.scientificbio.com).

## COMPANY PROFILES

Market Cap data as of August 30, 2022.  
\$ in millions USD

### SENESTECH (NASDAQ: SNES)

**Industrials | Market Cap: \$8M**

SenesTech is "The Pest Control Difference" for the 21st century. They are rodent fertility control specialists fueled by our passion to create a healthy environment by virtually eliminating rodent pest populations. We keep an inescapable truth in mind. Two rats can be responsible for the birth of up to 15,000 pups a year. SenesTech invented ContraPest®, the world's first and only U.S. EPA registered rodent contraceptive. ContraPest® fits seamlessly into all integrated pest management programs, greatly improving the overall goal of effective rodent management. We strive for clean cities, efficient businesses and happy households—all through non-lethal, proactive pest control. At SenesTech, they don't just eliminate rats. They make a better world.

### TAAL DISTRIBUTED INFORMATION TECHNOLOGIES (CSE: TAAL / OTCQX: TAALF)

**FinTech | Market Cap: \$37M**

TAAL Distributed Information Technologies Inc. is a vertically integrated blockchain technology company. It is engaged in the ownership and management of scalable professional-grade Blockchain Infrastructure upon which it strives to deliver value-added services supporting and enabling businesses to build customized blockchain-based solutions and applications for enterprise clients. TAAL's business model drives revenue by granting access to, and enabling the utilization of, a variety of proprietary products, Blockchain Infrastructure, platforms, licenses, and services. Blockchain networks need to support limitless scalability, unbounded transactional volume, and profits earned by those that process the most transactions (as opposed to operations with the highest Hashrate). TAAL has focused its attention and resources on the Bitcoin Satoshi Vision ("BSV") network protocol due to its highly scalable platform and lowest industry cost for developing fiat-based revenue. TAAL is dedicated to the BSV blockchain and supporting enterprises who build their custom cloud-based processing of blockchain data and transaction processing for use upon the BSV blockchain.

### VOLITIONRX (NYSE AMERICAN: VNRX)

**Healthcare | Market Cap: \$200M**

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring. Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market. For more information about Volition, visit Volition's website [volition.com](http://volition.com).

### VOX ROYALTY CORP. (TSXV: VOX / OTCQX: VOXCF)

**Basic Materials | Market Cap: \$100M**

Vox is a returns focused precious metals royalty company with a portfolio of over 50 royalties and streams spanning eight jurisdictions. The Company was established in 2014 and has since built unique intellectual property, a technically focused transactional team and a global sourcing network which has allowed Vox to target the highest return on invested capital in the royalty sector. Since the beginning of 2020, Vox has announced over 20 separate transactions to acquire over 50 royalties.

### XYBION DIGITAL INC. (TSXV: XYBN)

**Technology | Market Cap: \$110M**

Xybio is a global SaaS company that helps enterprise life sciences organizations accelerate new drug development into approved medicines that may save lives and keep employees safe. We digitize drug research and development, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that is cost-effective, ready to deploy, and easy to use. Xybio has over 160 clients in 29 countries using its low-code software to accelerate timelines, improve compliance, expand capacity, minimize operating risks, and reduce expenses while keeping employees safe.

### ZOOMD TECHNOLOGIES (TSXV: ZOMD / OTC: ZMDTF)

**Technology | Market Cap: \$42M**

Zoomd offers a site search engine to publishers, and a mobile app user acquisition platform, integrated with a majority of global digital media, to advertisers. The platform unifies more than 600 media sources into one unified dashboard. Offering advertisers, a user acquisition control center for managing all new customer acquisition campaigns using a single platform. By unifying all these media sources onto a single platform, Zoomd saves advertisers significant resources that would otherwise be spent consolidating data sources, thereby maximizing data collection and data insights while minimizing the resources spent on the exercise. Further, Zoomd is a performance-based platform that allows advertisers to advertise to the relevant target audiences using a key performance indicator-algorithm that is focused on achieving the advertisers' goals and targets.



## DISCLAIMER / DISCLOSURES

Services: Lytham Partners, LLC ("Lytham") provides a range of investor relations services to its clients. The particular services provided vary by client and may change from time to time. Compensation Information: Lytham is compensated by its clients for providing investor relations services. Click here for full compensation information: <https://lythampartners.com/disclosures/>. No Investment Advice: Lytham is not a registered broker-dealer, registered investment adviser or financial adviser, nor does it hold itself out to be. All materials presented on Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission are not to be regarded as investment advice, do not constitute an endorsement of the company, and are only for informative purposes. Before making a purchase or sale of any securities mentioned in Lytham's publications or presentations or on its website, Lytham strongly encourages and recommends consultation with a registered securities representative. Lytham's website and/or publications or presentations released by Lytham to the public through its website, email, or any other means of transmission do not constitute an offer to purchase or sell securities, and is not to be construed as a representation of an offer or a solicitation of any offer by Lytham or its client companies to purchase or sell any security. Lytham or any of its affiliates, members, employees, clients, officers, directors, and/or their respective families may from time to time purchase or sell, as agents or principals, or otherwise hold positions in, securities of its client companies, and are free to buy or sell those positions at will. Any such positions may be increased or decreased from time to time in the future without notice. Any information or opinions expressed on Lytham's website and/or publications or presentations released by Lytham are subject to change without notice. Lytham's full disclaimer/disclosures statement can be found on its website at <https://lythampartners.com/disclosures/>.

### CONTACT US!

For more information on our Fall 2022 Investor Conference, please call 602.889.9700 or email us at [conference@lythampartners.com](mailto:conference@lythampartners.com)